At the request of the exchanges, the U.S./Hong Kong stock quotes are displayed on a 15-minute delay, download the APP to view the real-time quotes for free.
Close
SLS SELLAS Life Sciences Group Inc.
Post-Market Trading 11-26 18:26:14 EST
1.20
+0.03
+2.56%
盘后1.20
+0.000.00%
17:33 EST
High1.20
Low1.16
Vol512.09K
Open1.18
D1 Closing1.17
Amplitude3.42%
Mkt Cap84.46M
Tradable Cap84.24M
Total Shares70.38M
T/O605.33K
T/O Rate0.73%
Tradable Shares70.20M
P/B--
ROE--
EPS0.00
52wk High--
52wk Low--
P/E--
Dividend--
Div.Yield--
ROA--
Billionaire Michael Bloomberg Wants to Crush Boeing's Space Dream
voxeljet, Dressler Group GmbH, Fraunhofer IPA and the University of Bayreuth Collaborate in Re-Processing of Discarded PA12 Powder for 3D Printing via High-Speed Sintering (HSS)
Sellas Announces U.S. FDA Rare Pediatric Disease Designation (Rpdd) Granted to Galinpepimut-S (Gps) for the Treatment of Pediatric Acute Myeloid Leukemia
SELLAS Life Sciences Group, Inc., a late-stage clinical biopharmaceutical company, focuses on the development of novel cancer immunotherapies for various cancer indications in the United States. The company's lead product candidate is galinpepimut-S (GPS), a cancer immunotherapeutic agent that targets Wilms tumor 1, which is in Phase 3 clinical trials for the treatment of acute myeloid leukemia; and in Phase 1/2 clinical trials for the treatment for ovarian cancer. It has a strategic collaboration with Merck & Co., Inc. to evaluate GPS as it is administered in combination with PD1 blocker pembrolizumab in a Phase 1/2 clinical trial enrolling patients in up to five cancer indications, including hematologic malignancies and solid tumors; and GenFleet Therapeutics (Shanghai), Inc. for the development and commercialization of GFH009, a highly selective small molecule CDK9 inhibitor, currently under Phase 1 clinical trials. The company is headquartered in New York, New York.